Under the Paperwork Reduction Act of 1995, no persons are required to re-

Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10582184
Filing Date		2007-09-26
First Named Inventor Samir		Bennabi
Art Unit		1625
Examiner Name	David	K O Dell
Attorney Docket Number		BHC 031069

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	7648986		2010-01-19	Nagarathnam et al.			
2 7737153		7737153	2010-06-15		Fuerer et al.			
	3 6924290				Nagarathnam et al.			
	4	7723347		2010-05-25	Schirok et al.			
If you wisl	u wish to add additional U.S. Patent citation information please click the Add button.				ease click the Add button.	Add		
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove		
Examiner Initial*	Cite No	Publication Kind Number Code1		Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20030125344		2003-07-03	Nagarathnam et al.			
	2	20080139595		2008-06-12	Schirok et al.			

U.S. PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

20050182040

20040014755

3

4

Examiner Cite Foreign Document

Application Number		10582184
Filing Date		2007-09-26
First Named Inventor	Samir Bennabi	
Art Unit		1625
Examiner Name	David K O Dell	
Attorney Docket Number		BHC 031069

Name of Patentee or

Remove

Pages,Columns,Lines

where Relevant

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Applicant of cited Document	where Relevant Passages or Relevant Figures Appear	T5
	1	2489452	CA		2003-12-24	BAYER SCHERING PHARMA AG		
If you wish	to a	dd additional Foreign	Patent Documer	nt citation	information p	lease click the Add butto	n Add	
			NON-PATE	ENT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No		ırnal, serial, sym	posium,	catalog, etc),	the article (when approp date, pages(s), volume-is		Τs
	1	US Patent Application	Serial No 11/587,	975, filed I	December 20, 2	007 (Attorney Docket No B	HC 041077)	
If you wish	n to a	dd additional non-pate	nt literature doc	ument cit	tation informat	ion please click the Add	button Add	
			E	XAMINE	R SIGNATUR	E		
Examiner	Signa	iture				Date Considered		\neg
						ormance with MPEP 609 with next communication		
Standard ST 4 Kind of doo	.3). 3 p	or Japanese patent docum	ents, the indication	of the year	of the reign of the	or office that issued the docume Emperor must precede the se ideard ST.16 if possible. 5 Appl	rial number of the patent door	ument.

2005-09-18

2004-01-22

Country

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

Imazaki et al.

FOREIGN PATENT DOCUMENTS

Kind Publication

Nagarathnam et al.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10582184
Filing Date			2007-09-26
	First Named Inventor	Samir	Bennabi
	Art Unit		1625
	Examiner Name	David	K O Dell
	Attorney Docket Number		BHC 031069

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CPR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CPR 1.97(c)(c)

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/KAREN B. KING/	Date (YYYY-MM-DD)	2012-01-09
Name/Print	Karen R King	Registration Number	41898

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1450, Alexandria, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1450, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.